Back to Authors

Obando, Jorge

A5015816850 | I170897317

Mayo Clinic

Duke University

Citations 2

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 753-782

10.6004/jnccn.2023.0034 | PMID 37433437

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.
Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 202-210

10.6004/jnccn.2019.0014 | PMID 30865919

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.